Generic Name and Formulations:
Pentostatin 10mg/vial; lyophilized pwd for IV inj after reconstitution; contains mannitol.
Indications for Pentostatin:
Active hairy cell leukemia.
Ensure adequate hydration. Give as IV bolus or infuse over 20–30 minutes after dilution. 4mg/m2 every other week. Reevaluate after 6 months; discontinue if complete or partial response not achieved; max duration of therapy 12 months. Withhold dose if ANC <200 cells/mm3; may resume when resolved.
Active infections; treat prior to initiating therapy. Withhold or discontinue therapy if severe rash or neurotoxicity develops. Renal impairment. Monitor and obtain CBCs, liver, and renal function before and during therapy. Pregnancy (Cat. D); avoid use. Nursing mothers: not recommended.
Concomitant fludarabine: not recommended. Potentiates vidarabine. Acute pulmonary toxicity and hypotension with carmustine, etoposide, and high dose cyclophosphamide (see literature).
GI upset, fever, rash, fatigue, leukopenia, pruritus, cough, myalgia, chills, headache, abdominal pain, anorexia, asthenia, stomatitis, rhinitis, dyspnea, anemia, pain, sweating, infections, thrombocytopenia.
Psychiatry Advisor Articles
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Buprenorphine, Methadone Combined With CNS Depressants May Lead to SAEs
- Vagus Nerve Stimulation in HIV-Associated Depression
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- Retirement Saving Behavior Associated With Psychological Distress